Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.4.24.56 (
insulin-degrading enzyme
)
737
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Insulin degrading enzyme (IDE) is an evolutionarily conserved, nonlysosomal metalloprotease that has been implicated in the cellular degradation and processing of insulin. However, the site and the mode of the action of this enzyme are unclear. We have addressed these questions by establishing several Ltk- cell lines that can overexpress human
insulin-degrading enzyme
(hIDE) upon glucocorticoid induction. The level of overexpression of hIDE protein and transcripts in these lines correlates well with an increase in insulin degradation in both cell lysates and intact cells. Comparison of the deduced amino acid sequences of mammalian and Drosophila IDEs reveals a conserved carboxyl-terminal peroxisomal targeting sequence (A/S-K-L), suggesting that IDE may be localized in peroxisomes. To test this possibility, we determined the cellular location of the stably transfected hIDE by both immunofluorescence and immunocryoelectron microscopy. The overexpressed hIDE predominantly colocalized with
catalase
in peroxisomes, although IDE was also found in the cytosol at a much lower concentration. These results demonstrate that stably transfected IDE catalyzes a rate-limiting step in cellular insulin degradation and is localized predominantly in peroxisomes.
...
PMID:Inducible expression and cellular localization of insulin-degrading enzyme in a stably transfected cell line. 807 10
Although insulin is degraded as a consequence of receptor-mediated endocytosis, the location and nature of the responsible proteinase(s) remain controversial. Insulin degrading enzyme (
IDE
; EC 3.4.22.11), a mainly cytosolic neutral thiol metalloendopeptidase of 110 kDa, has been proposed to be the main cellular clearance mechanism. However, endosomes concentrate and degrade internalized insulin demonstrating that
IDE
is unlikely to be the relevant enzyme for endosomal proteolysis of internalized insulin in liver parenchyma. In purified endosomal fractions insulin was actively degraded at acid pH and
IDE
was undetectable as evaluated by immunoblotting, immunoprecipitation, or chemical cross-linking procedures. Affinity purified endosomal acidic
insulinase
displayed a pH optimum of 4-5.5, a lack of inhibition by EDTA and N-ethylmaleimide, and a partial metal-ion requirement (for Mn2+) all of which distinguished it from
IDE
. A small but detectable presence of
IDE
in particulate nuclear (N) and large granule (ML) fractions was observed by differential centrifugation. By analytical centrifugation,
IDE
cosedimented with the organelle containing the peroxisomal marker proteins
catalase
and thiolase (median density, 1.21 g.cm-3). By preparative centrifugation, highly purified peroxisomes were observed to be enriched in
IDE
. Since all cloned cDNAs of
IDE
(human, rat, and Drosophila) reveal a deduced classical peroxisomal targeting sequence A/SKL at their carboxyl termini this may account for the peroxisomal location of
IDE
. Taken together, our studies identify an
insulin-degrading enzyme
in endosomes which is distinct from
IDE
. The latter's presence in peroxisomes suggests that its physiological substrate(s) in vivo are polypeptides other than insulin.
...
PMID:Endosomal proteolysis of insulin by an acidic thiol metalloprotease unrelated to insulin degrading enzyme. 830 Jun 32
The central role of peroxisomes in ROS and lipid metabolism and their importance in brain functioning are well established. The aim of this work was to study the modulation of peroxisomal and peroxisome-related proteins in cortical neurons in vitro challenged with chronic or acute Abeta treatment, in order to investigate whether peroxisomes represent one of the cellular target of Abeta in these cells. The expression of peroxisomal (PMP70,
catalase
, acyl-CoA oxidase and thiolase), peroxisome-related (PPARalpha,
insulin-degrading enzyme
) and anti-oxidant (SOD1, SOD2, GSTP1) proteins was studied. The results obtained, demonstrating an early upregulation of the peroxisomal proteins during the chronic challenge, followed by their dramatic impairment after acute challenge, suggest that peroxisomes represent one of the first line of defence against Abeta-mediated oxidative injury. Our results support the notion that substances able to activate PPARalpha and/or to induce peroxisomal proliferation may constitute a novel preventive and/or therapeutic tool against neurodegenerative diseases.
...
PMID:Neuronal response of peroxisomal and peroxisome-related proteins to chronic and acute Abeta injury. 1951 5